Fine post I,
Without a early co-partner for the TAVR R&D, this year, do you believe it will impact the cf+ forecast.
Big task perhaps, a answer, without knowing actual costs, though you could reasonably assume costs will rise as time goes by.
Perhaps another unwelcome part of the legacy of this company is the amount of capital that went towards the R&D of the vaccines, till funding was stopped and a partner eventually found.
Probability of success, development of this IP, imo, is high, though it will need to be funded soonest, for this to fail to attract a co-partner in the immediate future will hinder the immediate prospects of the company, imo, especially if lagging well into 2019.
Co-partner will definitely have to be a major entity, outside the top players, that has the footprint to accelerate this in a timely manner.
AHZ Price at posting:
25.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)